Radiopharm Theranostics Secures A$18.5 Million to Propel Phase III-Ready Brain Imaging Agent RAD101

Robust Capital Raise Bolsters Financial Position for Regulatory Milestones

In July 2026, Radiopharm Theranostics successfully completed a capital raise totaling A$18.5 million, consisting of a A$12.5 million institutional placement and a fully subscribed A$6.0 million share purchase plan. This funding boost increased the company’s pro-forma cash balance to A$28.5 million as of 3 July 2026, providing critical financial resources to advance its clinical pipeline through key regulatory milestones over the next 12 to 18 months, particularly the Phase III registration pathway for RAD101.

The timing of this capital raise coincides with significant clinical achievements and regulatory progress. The company indicated that the funds will support upcoming milestones, with investor confidence underscored by the successful completion of both placement and share purchase plan components. These developments were presented alongside clinical trial results and pipeline updates in a July 2026 multi-asset radiopharmaceutical platform presentation.

RAD101’s Phase IIb Success Paves Way for FDA Engagement and Phase III Trial Launch

RAD101, Radiopharm Theranostics’ lead diagnostic candidate, achieved a positive Phase IIb result in July 2026, with 93% or more of patients meeting the primary endpoint. This first-in-class PET imaging agent is designed to detect brain metastases and has demonstrated consistent clinical performance across interim analyses: 92% MRI concordance in December 2025 (11 of 12 patients) and 90% concordance in March 2026 (18 of 20 patients). The final Phase IIb data confirmed the primary endpoint achievement in an expanded cohort of 30 patients.

The regulatory pathway is advancing, with an FDA Phase III protocol alignment meeting scheduled for September 2026 and the registrational Phase III trial anticipated to start in Q4 2026. RAD101 has received FDA Fast Track designation, expediting its development and review for this serious unmet medical need. Additionally, a supply partnership with Siemens Healthineers, announced in April 2026, supports Phase III distribution and commercialization efforts in the U.S.

RAD101 Targets Large Unmet Market with No Direct Competitors

RAD101 addresses a significant market opportunity, with approximately 300,000 U.S. patients annually who could benefit from enhanced brain metastases imaging. Potential U.S. sales are projected to exceed US$500 million. The company positions RAD101 as a first-in-class agent with no direct competitors in this imaging space. Early and accurate detection of brain metastases is critical for oncology treatment planning and monitoring, highlighting the clinical importance of RAD101.

RAD101 employs an 18-fluorine (18F) PET isotope combined with a FASN tumor target and a pivalate-based targeting molecule. The 18-fluorine isotope offers practical clinical advantages due to its half-life, enabling regional distribution and compatibility with existing PET imaging infrastructure. The first-in-class status and lack of direct competition could provide substantial commercial upside upon regulatory approval and clinical adoption. The Siemens Healthineers partnership further ensures distribution infrastructure readiness for successful Phase III outcomes.

RAD204 Therapeutic Demonstrates Promising Early Clinical Efficacy in Phase I

RAD204, the lead therapeutic candidate targeting HER2-positive solid tumors, reported encouraging early efficacy data from its Phase I dose-escalation study. The first patient treated at 90 millicuries experienced a sustained tumor reduction of 43% or greater, with a second patient showing similar positive trends. RAD204 uses lutetium-177 (177Lu), a therapeutic radioisotope for targeted radiopharmaceutical therapy. Dose-escalation completion is expected in the first half of 2027.

HER2-positive solid tumors represent a validated oncology target, with HER2 known as a key driver in breast cancer and other malignancies. RAD204 offers a radiopharmaceutical therapeutic approach to this target. While early Phase I results are promising, further development is required to confirm safety and efficacy. The dose-escalation phase will define optimal dosing and safety before potential Phase II expansion.

Pipeline Expansion with Four Additional Phase I Therapeutics Targeting Oncology Markers

Beyond RAD204, Radiopharm Theranostics is advancing four additional Phase I therapeutic programs targeting validated oncology markers. RAD202 targets PD-L1-positive solid tumors with lutetium-177, aiming to complete dose escalation between Q4 2026 and Q1 2027, with efficacy data expected in Q4 2026. RAD402 targets KLK3 in prostate cancer using terbium-161 (161Tb), a novel therapeutic isotope, with dose escalation expected to finish in H2 2027. RV01 targets B7-H3 across solid tumors with lutetium-177, having dosed first patients in February 2026 and targeting dose escalation completion in H2 2027.

This multi-asset strategy offers multiple value-driving catalysts over the next 18 to 24 months, with defined clinical endpoints and readout timelines providing regular updates for investors. The use of diverse isotopes, including the emerging terbium-161 in RAD402, reflects the company’s commitment to optimizing radiopharmaceutical approaches for each indication. Clinical trial milestones are set sequentially from late 2026 through mid-2027, presenting a series of potential value inflection points.

RAD204 Represents First-in-Class Therapeutic with Significant Market Potential

RAD204 targets a first-in-class therapeutic opportunity with an estimated total addressable market of approximately US$10 billion. This market size reflects the prevalence of HER2-positive solid tumors across breast cancer, gastric cancer, and other malignancies. The first-in-class positioning and large market opportunity provide substantial commercial potential pending successful clinical development through Phase II and potentially Phase III.

RAD204’s radiopharmaceutical approach offers an alternative mechanism of action to existing anti-HER2 therapies, which include monoclonal antibodies and small-molecule agents. By utilizing therapeutic radioisotopes, RAD204 delivers a distinct biodistribution and tumor cell kill mechanism. Early Phase I efficacy signals, including the 43% or greater tumor reduction at 90 millicuries, support further clinical investigation. The upcoming dose-escalation phase will be critical to establish optimal dosing and safety profile.

Upcoming Regulatory and Partnering Milestones to Drive Value Through 2027

Key regulatory and commercial catalysts are anticipated between September 2026 and H1 2027. The FDA Phase III protocol alignment meeting for RAD101 is set for September 2026, followed by Phase III trial initiation in Q4 2026. Concurrently, the company plans to advance partnering and monetization discussions from Q4 2026 into early 2027. An M&A advisor has been retained to support these strategic discussions, indicating active pursuit of partnerships or potential acquisition opportunities.

These milestones mark Radiopharm Theranostics’ evolution from a clinical-stage developer with promising early data to a company approaching Phase III registration and commercial partnerships. Institutional investors involved in the capital raise are likely considering these near-term catalysts. The FDA alignment meeting is a pivotal regulatory event that could significantly influence trial feasibility and timelines. Successful partnering could provide additional capital, expertise, and commercial infrastructure to support Phase III execution and commercialization.

Consistent Clinical Progress and Milestone Delivery Since Mid-2025

Since mid-2025, Radiopharm Theranostics has consistently delivered clinical progress and milestones, as documented in ASX and GlobeNewswire announcements from July 2025 through April 2026. Notable achievements include dosing first patients in the RV01 Phase I/2a program (February 2026), RAD402 Phase I/2a program (March 2026), and establishing the Siemens Healthineers supply partnership (April 2026). These milestones demonstrate effective operational execution and simultaneous advancement of multiple programs.

This steady milestone delivery supports investor confidence in management’s ability to meet timelines for the anticipated Phase III commencement in Q4 2026 and subsequent regulatory and partnering milestones. Nonetheless, clinical development carries inherent uncertainties, and delays or unexpected results remain possible at any stage.

Investment Highlights and Risk Factors in Radiopharmaceutical Development

Radiopharm Theranostics’ investment case includes a multi-asset radiopharmaceutical platform with one Phase III-ready imaging lead and four clinical-stage therapeutics, strategic partnerships such as the Siemens Healthineers supply agreement, FDA Fast Track designation for RAD101, and encouraging Phase I efficacy data for RAD204. The company targets large unmet markets in brain metastases imaging and HER2-positive oncology therapeutics. The recent A$18.5 million capital raise ensures funding through key development milestones, with pro-forma cash of A$28.5 million as of 3 July 2026.

However, radiopharmaceutical clinical development involves risks including potential delays, unfavorable trial results, increased costs, and regulatory demands for additional data before approval. These risks are common to oncology drug development. The company’s success depends on completing Phase III trials, obtaining regulatory approvals, and achieving clinical adoption and commercialization.